Dr. Seth Pollack, MD
What this data tells you about Dr. Pollack
Dr. Seth Pollack is a hematology & oncology specialist in Chicago, IL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Pollack performed 33,956 Medicare services across 802 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pollack received a total of $120,895 from 14 pharmaceutical and/or device companies across 114 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pollack is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
10,500 | $1 | $5 |
| Nivolumab injection (Opdivo) | 6,680 | $24 | $97 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
4,500 | $38 | $170 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,200 | $0 | $7 |
| Pembrolizumab injection (Keytruda) | 2,800 | $43 | $171 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
2,340 | $36 | $134 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
593 | $4 | $174 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
420 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 320 | $1 | $76 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
250 | $4 | $10 |
| Injection, granisetron hydrochloride, 100 mcg | 200 | $0 | $5 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
180 | $75 | $821 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
119 | $109 | $940 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
118 | $13 | $143 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
110 | $96 | $323 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
98 | $2 | $8 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
84 | $17 | $129 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
70 | $24 | $203 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
68 | $53 | $410 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
64 | $1 | $3 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
45 | $60 | $326 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
44 | $146 | $434 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
41 | $12 | $88 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
34 | $23 | $215 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
22 | $54 | $464 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
16 | $43 | $100 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $45 | $132 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
14 | $67 | $219 |
| New patient office visit, complex (60-74 min) | 11 | $172 | $654 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2018-2024) ›
Associated products mentioned in payments ›
The majority of payments (62%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for hematology & oncology in IL.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pollack is a mixed practice specialist, with above-average Medicare volume (top 26% in IL), with speaking/promotional industry engagement in the top 8% of IL peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pollack experienced with iron infusion (injectafer)?
Does Dr. Pollack receive payments from pharmaceutical companies?
How do Dr. Pollack's costs compare to other hematology & oncology specialists in Chicago?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology